Rivaroxaban Market, By Indication (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Prophylaxis of Venous Thromboembolism, and Others), By Formulation, By Patient Type, By Distribution Channel, By Geography

Description

Global Rivaroxaban Market is estimated to be valued at USD 16.72 Mn in 2024 and is expected to reach USD 26.11 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 16.72 Mn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	6.60%	2031 Value Projection:	US$ 26.11 Mn

Figure. Rivaroxaban Market Share (%), By Region, 2024

The global Rivaroxaban market has been growing steadily over the past decade on the back of rising prevalence of deep vein thrombosis and pulmonary embolism disorders globally. Rivaroxaban is an oral anticoagulant that acts as an inhibitor of factor Xa in the blood coagulation pathway. It has emerged as a preferred alternative to warfarin for patients requiring anticoagulation therapy due to advantages such as fixed dosing without need for frequent monitoring. The drug is most commonly used to reduce risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and reduce recurrence of venous thromboembolism. With growing awareness about benefits of novel oral anticoagulants and increasing patient pool affected by target diseases, the rivaroxaban market is anticipated to continue expanding rapidly over the coming years.

Market Dynamics:

The global rivaroxaban market growth is driven by rising geriatric population who are more prone to thromboembolic disorders, growing preference for novel oral anticoagulants over traditional drugs like warfarin, and increasing number of surgical procedures performed worldwide. However, high costs associated with rivaroxaban therapy compared to generic drugs is a major factor limiting its widespread adoption. On the positive side, ongoing clinical trials evaluating rivaroxaban for additional indications and approval for new age groups are expected to create new opportunities. Moreover, development of modified dosage forms suited for specific patient types could help overcome challenges posed by high costs.

Key features of the study:

This report provides in-depth analysis of the global rivaroxaban market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global rivaroxaban market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Johnson & Johnson, Pfizer, Bayer, and Sanofi
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global rivaroxaban market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global rivaroxaban market.

Detailed Segmentation:

By Indication Insights (Revenue, USD Mn, 2019 - 2031)
- Atrial Fibrillation
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Prophylaxis of Venous Thromboembolism (VTE)
- Others (Acute Coronary Syndrome, etc.)
By Formulation Insights (Revenue, USD Mn, 2019 - 2031)
- Tablets
- Suspension
By Patient Type Insights (Revenue, USD Mn, 2019 - 2031)
- Adults
- Pediatrics
By Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
- Hospitals and Clinics
- Retail Pharmacies
- Online Pharmacies
By Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Bayer AG
- Janssen Pharmaceuticals, Inc.
- Interquim SA
- Natco Pharma
- Mylan N.V.
- Sandoz (a Novartis division)
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Hetero Labs Limited
- Fresenius Kabi AG
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals
- Reddy's Laboratories
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Pfizer Inc.
- Eisai Co., Ltd.
- Amgen Inc.

Product Code: CMI1962

1. RESEARCH OBJECTIVES AND ASSUMPTIONS

Research Objectives
Assumptions
Abbreviations

2. MARKET PURVIEW

Report Description
- Market Definition and Scope
Executive Summary
- Global Rivaroxaban Market, By Indication
- Global Rivaroxaban Market, By Formulation
- Global Rivaroxaban Market, By Patient Type
- Global Rivaroxaban Market, By Distribution Channel
- Global Rivaroxaban Market, By Region

3. MARKET DYNAMICS, REGULATIONS, AND TRENDS ANALYSIS

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Rivaroxaban Market, By Indication, 2024-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Atrial Fibrillation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Deep Vein Thrombosis (DVT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Pulmonary Embolism (PE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Prophylaxis of Venous Thromboembolism (VTE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others (Acute Coronary Syndrome, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

5. Global Rivaroxaban Market, By Formulation, 2024-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Rivaroxaban Market, By Patient Type, 2024-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Rivaroxaban Market, By Distribution Channel, 2024-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Rivaroxaban Market, By Region, 2019 - 2031, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2019 - 2031, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
GCC Countries
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Indication, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Formulation, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Patient Type, 2019 - 2031, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Mn)
South Africa
North Africa
Central Africa

9. COMPETITIVE LANDSCAPE

Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Janssen Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Interquim SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Natco Pharma
Mylan N.V.
Sandoz (a Novartis division)
Teva Pharmaceutical Industries Ltd.
Aurobindo Pharma
Zydus Cadila
Apotex Inc.
Hetero Labs Limited
Fresenius Kabi AG
Sun Pharmaceutical Industries Ltd.
Lupin Pharmaceuticals
Reddy's Laboratories
Bristol-Myers Squibb
Merck & Co., Inc.
Pfizer Inc.
Eisai Co., Ltd.
Amgen Inc.

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us